Germany's Boehringer Ingelheim and UK drug major GlaxoSmithKline havesigned a letter of intent for an accelerated development program for a co-package of Viramune (nevirapine) and Combivir (lamivudine/zidovudine) for the treatment of HIV infection in the developing world.
"The co-package of Viramune and Combivir is the most expeditious strategy for facilitating access to HIV treatment in the developing world," said Alessandro Banchi, chairman of the board of managing directors at BI. "In practice, the Viramune-Combivir co-package will facilitate distribution and delivery of a recognised triple therapy to patients in need," he added.
The Viramune and Combivir combination regimen is already a well-established treatment for HIV which is recommended as a first-line therapy by the World Health Organization in its guidelines for developing countries (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze